Assertio Therapeutics Inc
Could not find a ticker for this position, may be a filing error
A specialty pharmaceutical company, Assertio Therapeutics acquires, develops, and markets branded prescription medicines, including products for pain and inflammation. Founded in 1995 in California as Depomed, Inc., it built its early reputation on the "Acuform" drug-delivery platform that releases medicines slowly in the stomach. It renamed itself Assertio in 2018 — the name chosen to signal a bold, decisive new direction — and in 2026 its business was acquired by Zydus Lifesciences after the pain portfolio was sold to Cosette Pharmaceuticals.
2.5% Senior Convertible Notes due 2021
No 8-K or 6-K filings recorded.